[HTML][HTML] Deucravacitinib for the treatment of psoriatic disease
AM Lé, L Puig, T Torres - American Journal of Clinical Dermatology, 2022 - Springer
Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
[HTML][HTML] Deucravacitinib for the Treatment of Psoriatic Disease
AM Lé, L Puig, T Torres - American Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
Deucravacitinib for the Treatment of Psoriatic Disease.
L Puig, T Torres - American Journal of Clinical Dermatology, 2022 - europepmc.org
Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
[PDF][PDF] Deucravacitinib for the Treatment of Psoriatic Disease
AM Lé, L Puig, T Torres - American Journal of Clinical …, 2022 - researchgate.net
Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
Deucravacitinib for the Treatment of Psoriatic Disease
AM Lé, L Puig, T Torres - American journal of clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …